IN2008CN05409A - - Google Patents

Download PDF

Info

Publication number
IN2008CN05409A
IN2008CN05409A IN5409CHN2008A IN2008CN05409A IN 2008CN05409 A IN2008CN05409 A IN 2008CN05409A IN 5409CHN2008 A IN5409CHN2008 A IN 5409CHN2008A IN 2008CN05409 A IN2008CN05409 A IN 2008CN05409A
Authority
IN
India
Prior art keywords
compositions
conjugates
drugs
useful
addiction
Prior art date
Application number
Other languages
English (en)
Inventor
Martin F Bachmann
Patrik Maurer
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IN2008CN05409A publication Critical patent/IN2008CN05409A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN5409CHN2008 2002-07-18 2003-07-18 IN2008CN05409A (en, 2012)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39657502P 2002-07-18 2002-07-18
PCT/EP2003/007850 WO2004009116A2 (en) 2002-07-18 2003-07-18 Hapten-carrier conjugates comprising virus like particles and uses thereof

Publications (1)

Publication Number Publication Date
IN2008CN05409A true IN2008CN05409A (en, 2012) 2015-10-02

Family

ID=30770921

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5409CHN2008 IN2008CN05409A (en, 2012) 2002-07-18 2003-07-18

Country Status (16)

Country Link
US (4) US6932971B2 (en, 2012)
EP (2) EP2392345A3 (en, 2012)
JP (1) JP5084103B2 (en, 2012)
KR (2) KR20120041739A (en, 2012)
CN (2) CN100518823C (en, 2012)
AU (1) AU2003250106B2 (en, 2012)
BR (1) BR0312297A (en, 2012)
CA (1) CA2487849A1 (en, 2012)
IL (1) IL165249A0 (en, 2012)
IN (1) IN2008CN05409A (en, 2012)
MX (1) MXPA04012010A (en, 2012)
NZ (1) NZ537003A (en, 2012)
PL (1) PL375598A1 (en, 2012)
RU (2) RU2326693C2 (en, 2012)
WO (1) WO2004009116A2 (en, 2012)
ZA (1) ZA200409389B (en, 2012)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
AU2001252458A1 (en) * 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
AU2003242742B2 (en) * 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
CN102061288A (zh) * 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
KR20120041739A (ko) * 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
MXPA05000819A (es) * 2002-07-19 2005-08-29 Cytos Biotechnology Ag Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6.
NO346973B1 (en) 2002-12-20 2023-03-20 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
US7923109B2 (en) * 2004-01-05 2011-04-12 Board Of Regents, The University Of Texas System Inorganic nanowires
GB0419199D0 (en) * 2004-08-27 2004-09-29 Curidium Ltd Methods of diagnosis
WO2006037787A2 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
NZ554386A (en) * 2004-10-25 2009-12-24 Cytos Biotechnology Ag Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20060111271A1 (en) * 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US20060154259A1 (en) * 2005-01-07 2006-07-13 Huan-Cheng Chang Diamond crystallites for biotechnological applications
EP2502621A1 (en) * 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Crystalline forms of bupropion HBr
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
ZA200802225B (en) * 2005-09-28 2009-10-28 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
EP2007435B1 (en) 2006-03-31 2019-12-18 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2007117581A2 (en) * 2006-04-06 2007-10-18 Collegium Pharmaceutical, Inc. Stabilized transdermal bupropion preparations
EP1849780A1 (en) 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20080087279A1 (en) * 2006-10-11 2008-04-17 Tieck Catharine Laureen Johnso Metered dose inhaler
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
WO2008079324A1 (en) * 2006-12-21 2008-07-03 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP1982729A1 (en) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
US9707299B2 (en) * 2007-05-23 2017-07-18 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
CA2917512A1 (en) 2007-10-12 2009-04-23 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009070533A1 (en) * 2007-11-29 2009-06-04 Complegen, Inc. Methods of inhibiting steroyl coa desaturase
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
US20090270264A1 (en) * 2008-04-09 2009-10-29 United States Army As Represenfed By The Secretary Of The Army, On Behalf Of Usacidc System and method for the deconvolution of mixed dna profiles using a proportionately shared allele approach
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US20110182918A1 (en) 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
US20100009389A1 (en) * 2008-07-14 2010-01-14 Masood Unnabi Khan Method of Making and Using Versatile Positive Controls and Antibody Detection Assays
KR20110045039A (ko) * 2008-08-08 2011-05-03 노파르티스 아게 니코틴계 합텐의 제조 방법
WO2010042743A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric multiplexes, compositions, and methods for using same
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
CN101413946B (zh) * 2008-10-31 2012-08-08 江南大学 一种盐酸西布曲明的酶联免疫检测方法
US8151804B2 (en) * 2008-12-23 2012-04-10 Williams Jonnie R Tobacco curing method
PL222496B1 (pl) * 2009-04-10 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną
CN102686244A (zh) * 2009-04-21 2012-09-19 西莱克塔生物科技公司 提供一种Th1-偏向性应答的免疫纳米疗法
US20110020388A1 (en) 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP2459215A1 (en) * 2009-07-31 2012-06-06 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
US9125907B2 (en) * 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
WO2011050158A1 (en) 2009-10-22 2011-04-28 The Trustees Of Columbia University In The City Of New York Anti-drug vaccines
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
AR081809A1 (es) 2010-03-29 2012-10-24 Inst Nat Sante Rech Med Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
JP6324068B2 (ja) 2010-05-26 2018-05-23 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 合成ナノキャリア混合ワクチン
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
MX356426B (es) 2011-04-04 2018-05-29 Univ Iowa Res Found Metodos para mejorar inmunogenicidad de vacuna.
TWI488865B (zh) * 2011-06-16 2015-06-21 Nat Univ Chung Hsing 經改造之油體鈣蛋白（ｃａｌｅｏｓｉｎｓ）及其用於半抗原之抗體製造
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
JP6170932B2 (ja) * 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
MX358762B (es) * 2011-12-21 2018-09-03 Apse Llc Procesos que utilizan vlps con cápsides resistentes a hidrolasas.
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
KR102090849B1 (ko) 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US20160051693A1 (en) 2013-03-21 2016-02-25 Genisphere, Llc Cellular Delivery of DNA Intercalating Agents
EP3222274B1 (en) 2013-06-19 2020-10-21 Apse Llc Compositions and methods using capsids resistant to hydrolases
EP3041478A4 (en) * 2013-09-05 2017-04-26 Immune Design Corp. Vaccine compositions for drug addiction
MX373017B (es) * 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
JP6476194B2 (ja) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
EP3283125B1 (en) 2015-04-17 2021-12-29 CureVac Real Estate GmbH Lyophilization of rna
CN107921237A (zh) 2015-04-27 2018-04-17 反射医学公司 交感神经心肺神经调节系统和方法
US10729654B2 (en) 2015-05-20 2020-08-04 Curevac Ag Dry powder composition comprising long-chain RNA
SG10201910431RA (en) 2015-05-20 2020-01-30 Curevac Ag Dry powder composition comprising long-chain rna
CN104897864B (zh) * 2015-06-18 2016-08-31 北京勤邦生物技术有限公司 检测金刚烷胺的酶联免疫试剂盒及其应用
CN108884127A (zh) * 2016-01-21 2018-11-23 斯克利普斯研究院 合成的阿片类疫苗
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
EP3478287A4 (en) 2016-06-29 2020-04-08 Tulavi Therapeutics, Inc. TREATMENT OF SEPTICEMIA AND ASSOCIATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMOUS NERVOUS SYSTEM
US11602559B2 (en) * 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
CN107501409A (zh) * 2017-09-06 2017-12-22 杨蕾 一种尿酸人工抗原的制备方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN107982517B (zh) * 2017-12-15 2020-03-06 苏州科技城医院 治疗心肌缺血型慢性心力衰竭的西药复方组合物
AU2019299519B2 (en) 2018-07-02 2025-03-06 Incept Llc Methods and devices for in situ formed nerve cap
US20210315587A1 (en) 2018-07-02 2021-10-14 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap with rapid release
CN109884021A (zh) * 2019-03-29 2019-06-14 铁道警察学院 一种量子点标记的thc包被抗原、其制备方法及利用其检测食品中大麻含量的方法
CA3138100A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2021178257A1 (en) * 2020-03-02 2021-09-10 Unm Rainforest Innovations Virus-like particle vaccines for opioid drugs
CN111363011B (zh) * 2020-03-13 2021-08-24 北京大学 一种甲基苯丙胺疫苗及其制备方法与应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
CN118754841A (zh) 2020-05-19 2024-10-11 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
EP4157348A4 (en) * 2020-05-27 2024-06-19 Behnam, Babak COMPOSITIONS AND METHODS FOR TREATING MORPHINE, HEROIN AND ALCOHOL ADDICTION
CN112924665B (zh) * 2021-02-19 2023-10-03 山东莱博生物科技有限公司 一种抗体辣根过氧化物酶标记物及其制备与应用
CN114344288B (zh) * 2022-01-25 2023-07-04 深圳技术大学 盐酸多塞平在制备抗病毒药物中的应用
CN114907255A (zh) * 2022-04-25 2022-08-16 杭州同舟生物技术有限公司 一种利他林人工半抗原、人工抗原及其制备方法和应用
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
WO2025111546A1 (en) * 2023-11-22 2025-05-30 Board Of Trustees Of Michigan State University Development of broad-spectrum anti-opioid vaccines

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US157479A (en) * 1874-12-08 Improvement in fire-proof shutters
US64533A (en) * 1867-05-07 William s
US388866A (en) 1888-09-04 O o o o o o oop o o q o o q q
US175290A (en) * 1876-03-28 Improvement in rotary postmarking and canceling presses
US81295A (en) * 1868-08-18 bob in son
US175711A (en) * 1876-04-04 Improvement in bale-ties
US64529A (en) * 1867-05-07 hellen
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US4197237A (en) 1973-06-01 1980-04-08 Syva Company Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
WO1988001873A1 (en) 1986-09-22 1988-03-24 Emory University Vaccine and method of preparation
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
JPH0656106B2 (ja) 1988-10-29 1994-07-27 マツダ株式会社 過給機付エンジンの吸気装置
CA2005726A1 (en) * 1988-12-21 1990-06-21 Haruo Tomita Thermoplastic resin composition
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69018926T2 (de) 1989-09-04 1995-08-24 Wellcome Found Vakzine gegen Bordetella.
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
GB9001694D0 (en) * 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
CH678394A5 (en, 2012) 1990-08-22 1991-09-13 Cerny Erich H
US6699474B1 (en) * 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
AU1992592A (en) 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
US5232082A (en) * 1992-01-28 1993-08-03 Philip Morris Incorporated Pinless belt feeder
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US6210677B1 (en) * 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US5506268A (en) 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
AT402898B (de) 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CA2216658C (en) * 1995-03-31 2008-05-13 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
ATE230417T1 (de) 1996-03-01 2003-01-15 Novartis Erfind Verwalt Gmbh Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
CA2220768A1 (en) 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2255181T3 (es) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CN1155410C (zh) 1997-10-03 2004-06-30 卡里药品公司 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
CA2320488C (en) * 1998-02-12 2007-03-06 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
US6231964B1 (en) * 1998-06-30 2001-05-15 Ncr Corporation Thermal transfer ribbons with large size wax or resin particles
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
EP1135162B1 (en) 1998-11-30 2008-10-29 Cytos Biotechnology AG Ordered molecular presentation of allergens, method of preparation and use
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
NZ512056A (en) 1998-12-04 2004-01-30 Biogen Inc HBV core antigen particles with multiple immunogenic components attached via peptide ligands
IL145025A0 (en) 1999-02-25 2002-06-30 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6613742B1 (en) 1999-04-07 2003-09-02 Thomas Jefferson University Chemokine-derived synthetic peptides
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
MEP30408A (en) 2000-02-21 2010-10-10 Pharmexa As Novel method for down-regulation of amyloid
AU784345B2 (en) 2000-04-07 2006-03-16 University Of Leeds Innovations Limited Hepatitis B core antigen fusion proteins
AU2001252458A1 (en) * 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
JP2004500868A (ja) 2000-06-22 2004-01-15 セルテック　ファーマスーティカルズ　リミテッド Ｂ型肝炎コア抗原の修飾
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2002058635A2 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
RU2197268C1 (ru) * 2001-12-07 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения никотинизма
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
WO2003082329A2 (en) * 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
CN102061288A (zh) 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
KR20120041739A (ko) * 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
MXPA05000819A (es) 2002-07-19 2005-08-29 Cytos Biotechnology Ag Composiciones de vacunas que contienen arreglos de antigeno amiloide beta 1-6.
US20040076645A1 (en) 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates

Also Published As

Publication number Publication date
PL375598A1 (en) 2005-12-12
AU2003250106A1 (en) 2004-02-09
WO2004009116A2 (en) 2004-01-29
CN101574518B (zh) 2012-08-22
CN100518823C (zh) 2009-07-29
US6932971B2 (en) 2005-08-23
US7452541B2 (en) 2008-11-18
RU2326693C2 (ru) 2008-06-20
ZA200409389B (en) 2007-01-31
CN1668331A (zh) 2005-09-14
WO2004009116A3 (en) 2004-03-18
EP2392345A2 (en) 2011-12-07
US20050281845A1 (en) 2005-12-22
RU2008101922A (ru) 2009-07-27
JP2006504654A (ja) 2006-02-09
IL165249A0 (en) 2005-12-18
CA2487849A1 (en) 2004-01-29
MXPA04012010A (es) 2005-03-07
CN101574518A (zh) 2009-11-11
BR0312297A (pt) 2005-04-12
KR20120041739A (ko) 2012-05-02
US20100129395A1 (en) 2010-05-27
EP1523334A2 (en) 2005-04-20
EP2392345A3 (en) 2012-03-07
AU2003250106B2 (en) 2009-11-26
RU2005104430A (ru) 2005-08-10
US8187607B2 (en) 2012-05-29
NZ537003A (en) 2008-03-28
US20130142821A1 (en) 2013-06-06
KR101228376B1 (ko) 2013-01-31
JP5084103B2 (ja) 2012-11-28
KR20050027169A (ko) 2005-03-17
US20040059094A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
IN2008CN05409A (en, 2012)
EP1594542A4 (en) ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO1998014216A3 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
MXPA01005511A (es) Conjugados de hapteno-portador para tratar y prevenir la adiccion a la nicotina.
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DK1329226T3 (da) Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
DE59107814D1 (de) Impfstoff gegen drogen
MXPA05013200A (es) Derivados de estaurosporina para sindrome hipereosinofilico.
NO20043707L (no) Nye immuno effektor forbindelser
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
WO2004029214A8 (en) Lfa-1 alpha subunit antibodies and methods of use
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
WO2005042028A3 (en) Il-13 conjugated to an immunogen and uses thereof
SG156658A1 (en) Treatment of diseases
RU99127690A (ru) Способ лечения опийной наркомании
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer